Navigation Links
Head of Process Sciences at aTyr Pharma to Speak at Bio Korea 2009
Date:9/1/2009

SAN DIEGO, Sept. 1 /PRNewswire/ -- Chulho Park, Ph. D., Head of Process Sciences at aTyr Pharma, a privately held biopharmaceutical company focused on discovery and development of a newly emerging class of natural biotherapeutics, will be a featured speaker at Bio Korea 2009. On September 18, 2009, Dr. Park will present his talk "Selecting the Optimal Biotherapeutic Candidate for Development" at the conference, taking place in Seoul, Korea. In his presentation, Dr. Park will discuss key steps required to create a development process for a new biotherapeutic, and how he has applied his experience to optimizing the development pathway for the lead program at aTyr Pharma. aTyr's lead program, scheduled for a pre-IND meeting at the FDA in September, is a novel protein therapeutic, ATYR0030, with thrombopoietic activity that is initially being developed to treat thrombocytopenia in patients with myelodyspastic syndromes (MDS).

After completing a Ph. D. at Korea University and postdoctoral training at Stanford University, Dr. Park has spent 9 years in the pharmaceutical industry focused on process development for biotherapeutics, including experience with 8 proteins that have reached the clinical development stage. According to Alain Vasserot, Ph. D., Executive Director of Preclinical Development at aTyr Pharma, "Dr. Park adds valuable drug development expertise to aTyr Pharma. His experience and perspective have been an essential driver in our rapid development of ATYR0030. Dr. Park's talk at Bio Korea 2009 will give attendees a prime opportunity to gain perspective from a highly skilled practitioner in the biotherapeutic development field."

Jeff Watkins, the CEO of aTyr Pharma adds, "Dr. Park is a vital component of our strong biologics development team, a strength that distinguishes aTyr Pharma from many other biotechnology companies. With the current emphasis on protein biologics, most pharmaceutical companies are looking to novel biotherapeutics to provide new treatments for human diseases. Scientific leaders in our sector understand the unique issues and challenges associated with process development for protein therapeutics, and we are pleased that the organizers of Bio Korea 2009 recognize the value of sharing Dr. Park's perspectives in biotherapeutic development."

About aTyr Pharma

aTyr Pharma, Inc. is a biopharmaceutical company focused on the discovery of an entirely new class of biologics. aTyr Pharma's discovery engine for new biotherapeutics consists of novel proteins in the family of tRNA synthetases with cell signaling activities distinct from the protein synthesis activities commonly associated with the tRNA synthetases. These resected proteins, or "resectins," are being developed as novel therapeutics to treat hematological disorders, neurodegenerative diseases, inflammation, cardiovascular diseases and metabolic disorders.

www.atyrpharma.com


'/>"/>
SOURCE aTyr Pharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
2. Raydiance Collaborates With Rutgers University and Nations Largest Tissue Bank to Develop Innovative Tissue Processing Approaches
3. InVitria Showcases Cell Culture Productivity Enhancers at BioProcess International
4. Brain Waves Show Sound Processing Abnormalities in Autistic Children
5. Stress-Related Disorders Affect Brains Processing of Memory
6. Verification Studies of IntelligentMDxs Proprietary Molecular Diagnostic Assay Process Have Been Completed
7. Processed Tomato Products May Protect Against Inflammation, According to a Study Presented at the Experimental Biology Meeting
8. Smithfield Sends Update to Employees on Testing Process at Veracruz Joint Venture
9. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
10. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
11. Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... 2017  Caris Life Sciences ® , a leading ... of precision medicine, today announced that St. Jude Medical ... Alliance™ (POA) as its 17 th member. Through ... Crosson Cancer Institute will help develop standards of care ... profiling, making cancer treatment more precise and effective. ...
(Date:10/10/2017)... 2017   West Pharmaceutical Services, Inc. (NYSE: ... drug administration, today shared the results of a study ... the intradermal administration of polio vaccines. The study results ... May 2017 by Dr. Ondrej Mach , Clinical ... Organization (WHO), and recently published in the journal ...
(Date:10/4/2017)... Mass. , Oct. 4, 2017  According to the Centers for ... the end of October . PhysicianOne Urgent Care is helping communities across ... Westchester, NY , by offering no-cost* flu shots through the ... as mandated by certain health insurance regulations. ... The best time to get a flu shot is by the ...
Breaking Medicine Technology:
(Date:10/12/2017)... Francisco, CA (PRWEB) , ... October 12, 2017 ... ... Dr. Cheng, are now treating sleep apnea using cutting-edge Oventus O2Vent ... apnea, a serious sleep disorder characterized by frequent cessation in breathing. Oral appliances ...
(Date:10/12/2017)... WAUSAU, Wis. (PRWEB) , ... October 12, 2017 ... ... formulated standard products to meet the demand of today’s consumer and regulatory authorities ... team of probiotic experts and tested to meet the highest standard. , ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... The American ... Excellence to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium ... 8. , In honor of Morris F. Collen, a pioneer in the field of ...
(Date:10/12/2017)... ... 2017 , ... Information about the technology: , Otomagnetics has ... prevention of a major side effect of chemotherapy in children. Cisplatin and carboplatin ... cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. Hearing ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader ... a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were ... 11, 2017. , The annual award competition recognizes editorial and design excellence across a ...
Breaking Medicine News(10 mins):